Burla, Goutham Kumar Reddy
Shrestha, Dev
Bowen, Mayumi
Horvath, Joshua D.
Martin, Bryn A.
Funding for this research was provided by:
Genentech
Article History
Received: 2 November 2023
Accepted: 16 June 2024
First Online: 26 July 2024
Declarations
:
: Not applicable.
: All authors have approved the manuscript submission. The content of this manuscript has not been published or submitted for publication elsewhere.
: BAM is an employee at Alcyone Therapeutics. BAM is Principal Officer of Flux Neuroscience, LLC owner and holding company of the in vitro model IP used in this study. BAM has received research funding from Biogen Inc., Genentech Inc., Voyager Therapeutics, KBR Wyle, Alcyone Lifesciences Inc., Minnetronix Inc., and Voyager Therapeutics. BAM has served as a consultant to Flux Neuroscience, Genentech, Roche, Minnetronix, SwanBio Therapeutics, Praxis Medicines, Cerebral Therapeutics, CereVasc, InviCRO, Neurosyntec, Behavior Imaging, Anuncia Medical, and Voyager Therapeutics. BAM has been a scientific advisory board member for Alcyone Lifesciences, Anuncia Medical, Chiari and Syringomyelia Foundation, The International Society for Hydrocephalus and CSF Disorders, and The International CSF Dynamics Society. DS has received research funding from Genentech Inc.